2,833 publications from this institution
The administration of drotrecogin alfa (activated) to patients with severe sepsis was associated with a significant survival benefit that tended to increase with higher baseline likelihood of death. Current data suggest that the increased risk of bleeding does not vary according to likelihood of death.
info:eu-repo/semantics/published
<b>Introduction</b>: Despite considerable advances in our understanding of how sepsis develops and multiple clinical trials of potential therapies, no new pharmacologic agent has been consistently shown to improve survival. <b>Areas covered</b>: We reviewed relevant publications identified through PubMed and from the authors' knowledge of this field. We discuss the main reasons why clinical trials on new therapeutic interventions have failed in the past, including heterogeneity of study populations and choice of outcome measures. We discuss how changes in study design and in patient selection could help improve identification of effective agents in the future. <b>Expert opinion</b>: The search for new sepsis therapies must continue but lessons must be learned from previous clinical trials so that the same mistakes are not repeated. Rather than grouping all patients with sepsis together, we should study only those most likely to benefit from the intervention. Better characterization of patients will be facilitated using modern 'omics technology and analysis of the increasingly large quantities of clinical data available, enabling more personalized patient selection for trial inclusion. New clinical trial design and inclusion of other endpoints in addition to mortality will also aid our search for the elusive positive clinical trial and effective interventions for sepsis.
SCOPUS: le.j
Improved ICU prognostication, enabled by advanced ML/AI methods, offer a promising approach to inform difficult and urgent decisions under uncertainty. However, critical knowledge gaps around performance, equity, safety, and effectiveness must be filled and prospective, randomized testing of predictive interventions are still needed.
The incidence of fungal infections in the intensive care unit (ICU) is increasing, and systemic infection is associated with considerable morbidity and mortality. The diagnosis of fungal infection remains difficult in the absence of specific techniques able to distinguish colonization from invasive and disseminated disease. The treatment of fungal infections can be considered as prophylactic, early presumptive, empiric, or definitive. Several anti-fungal agents are effective, including amphotericin B and fluconazole, and others will be available in the near future. Immunomodulatory therapies are under investigation. We review the epidemiology, diagnosis and management of infections caused by the most common fungal pathogens, Candida and Aspergillus, in ICU patients.
Vincent Jean. Chatelliers (Les)-Châteaumur (Vendée). Donjon de Châteaumur. In: Archéologie médiévale, tome 29, 1999. p. 326.
Course Content: The aim of this refresher course is to review the essentials of cardiovascular and respiratory physiology applied to the comprehensive care of the critically ill patient. The target audience includes residents in training in intensive care medicine. There will be ample time for discussion after each lecture and during the clinical demonstrations.